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Abstract
Cyclin A2 is essential at two critical points in the somatic cell cycle: during S phase, when it activates CDK2, and during the
G2 to M transition when it activates CDK1. Based on the crystal structure of Cyclin A2 in association with CDKs, we
generated a panel of mutants to characterize the specific amino acids required for partner binding, CDK activation and
subcellular localization. We find that CDK1, CDK2, p21, p27 and p107 have overlapping but distinct requirements for
association with this protein. Our data highlight the crucial importance of the N-terminal a helix, in conjunction with the a3
helix within the cyclin box, in activating CDK. Several Cyclin A2 mutants selectively bind to either CDK1 or CDK2. We
demonstrate that association of Cyclin A2 to proteins such as CDK2 that was previously suggested as crucial is not a
prerequisite for its nuclear localization, and we propose that the whole protein structure is involved.
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Introduction
Cyclin-dependent kinases (CDK), that govern progression
through the cell cycle, are mainly controlled by transient
interactions with cyclin regulatory subunits and by reversible
phosphorylation reactions [1,2]. The specific functions of Cyclin
A2 protein at different stages of the cell cycle are dependent upon
its CDK partner. Cyclin A2 is essential for at least two critical
points in the somatic cell cycle: during the S phase, when it
activates CDK2, and during the G2 to M transition when it
activates CDK1. Cyclin A2 localizes predominantly to the nucleus
during the S phase where it regulates the initiation and progression
of DNA synthesis [3]. Phosphorylation of components of the DNA
replication machinery such as CDC6 by Cyclin A-CDK is
believed to be important to ensure only one round of DNA
replication per cell cycle. At the end of G2, Cyclin A2 relocalizes
to the centrosomes in the cytoplasm, where it binds to the poles of
mitotic spindles. A recent study demonstrated the implication of
Cyclin A2 in the activation of the M-phase promoting complex
composed of Cyclin B and CDK1 and that regulates G2-M
transition [4]. Finally, phosphorylation of CDH1 by Cyclin A2-
associated kinase prevents the formation of APC
CDH1 and
therefore delays cyclin B ubiquitination and degradation [5,6].
Expression of Cyclin A2 is ubiquitous, and is essential for
embryonic development, the null embryos dying at around day
5.5 post-coitum [7]. A recently published work using mice with
conditional Cyclin A2 alleles, while pointing to the compensatory
effect brought about by Cyclin E2 in Cyclin A2 deficiency,
confirmed its absolute requirement not only in early embryonic
development but also in the establishment of the hematopoietic
lineage [8].
In multicellular organisms the activity of these cyclin–CDK
complexes is precisely controlled at many levels, including cell-
cycle regulated transcription, programmed proteolytic destruction,
and even sub-cellular localization of cyclins. Cyclin A2 is tightly
regulated at the transcriptional level during the cell cycle [9,10]. Its
mRNA level increases at the G1/S transition and peaks during the
S phase. Cyclin A2 transcriptional regulation is modulated at the
G1/S transition by peripheral cues such as growth factors, TGF-b
as well as cell interactions with the extra-cellular matrix [11,12].
Transcriptional repression of Cyclin A2 involves promoter-bound-
complexes, which include E2F- and pRb-related proteins, as well
as chromatin remodelling factors such as Brahma/SNF2a [10,13].
The crystal structure of Cyclin A2, either isolated or associated
to CDK2 [14,15] is characterized by a rigid globular structure,
except for its N-terminal part. The globular part of the protein is
comprised of two sub domains: the cyclin box, conserved among
cyclins, and the cyclin box fold. They both consist of 5 a helices.
An additional a helix was found in the N-terminal half of the
protein [14,15]. Further studies based on mutagenesis approaches
stressed the importance of the conserved cyclin box region, with a
particular emphasis on the MRAIL motif localized within its
hydrophobic patch [16] [17]. In addition, it was suggested that the
N-terminal helix located upstream of this conserved region,
interacts also with CDKs [18].
Immunofluorescence studies have shown that Cyclin A2 is a
nuclear protein. However, it was also shown to play a role in the
cytoplasm by regulating centrosome duplication [19]. In this
context, it is worth mentioning the recently described protein,
SCAPER that associates to Cyclin A2 exclusively in the cytoplasm.
A full functional significance of this interaction remains unknown
although it was suggested that SCAPER might buffer the
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nuclear and cytoplasmic functions for Cyclin A2 and highlight the
importance of its correct cellular localization. Cyclin A2 has no
Nuclear Localization Signal (NLS) and it has been proposed that
its nuclear localization correlates with its ability to form complexes
with CDK partners [21]. In a recent study, Jackman et al.
demonstrated that Cyclin A2 actually shuttles between the nucleus
and cytoplasm thanks to its association with CDK2. Moreover, it
was shown that nuclear import is predominant with respect to the
export, resulting in a net nuclear localization as revealed by
immunofluorescence analysis [17]. However, mechanisms con-
trolling this translocation remain unknown due to the fact that
CDK2 has no evident NLS signal either. It was also proposed that
nuclear localization of Cyclin A2 correlates with its ability to
interact with p107 [22]. In addition to p107, other Cyclin A2
partners with evident NLS such as p130, p21 or members of the
E2F family were likely candidates for nuclear carriers [22].
In this study, using a mutagenesis approach on mouse Cyclin
A2 cDNA, we delineated the domains and amino acids this protein
required for its association to CDK1 and CDK2, for the induction
of CDK kinase activity, and for its subcellular localization. We
show that, aside from the hydrophobic region of the cyclin box
(MRAIL), both the N-terminal and its a3 helices play also a crucial
role in kinase activation. Interestingly, we were able to identify
amino acid residues responsible for a differential binding of Cyclin
A2 to CDK1 and CDK2. We also identified alleles of Cyclin A2
able to associate but not to activate these kinases, which is
consistent with a two-step mechanism of CDK activation (binding-
conformation change). We demonstrated that association to p21 or
p107 is not a prerequisite for nuclear localization of Cyclin A2.
Moreover, depletion of CDK2, p27 or both proteins had no effect
on it either. Furthermore, truncation or deletion of various parts of
Cyclin A2 failed to delineate a precise region mediating a proper
nuclear localization, thus pointing to the involvement of the whole
protein in this process.
Results
Construction of the different Cyclin A2 mutant cDNAs
In order to study critical amino residues necessary for Cyclin A2
interaction with its known partners, an intensive directed
mutagenesis was performed. In addition to single amino acid
substitutions, combinations of double or triple point mutations
were performed. Mutations spanned the cyclin box (a1, a3 and a5
helices) as well as the N-terminal a helix (Figure 1). Mutations
D171A and E180A (E167A and E176A in Xenopus Cyclin A
respectively), as well as Triple, M200A, L204A, W207A (M210A,
L214A, W217A in human Cyclin A2) were already described in
the literature [16,18]. All Cyclin A2 cDNAs were Flag-tagged.
Partners binding and kinase-activating abilities of Cyclin
A2 mutants
Capability of mutated Cyclin A2 protein to associate with its
endogenous partners was tested in co-immunoprecipitation assays
after transfection in NIH3T3 cells. Flag-tag was used to specifically
precipitate mutant Cyclin A2 and discriminate it from the
endogenous Cyclin A2 protein. For kinase activating assays, H1
histone was used as a template.
Interestingly two kinases that associate with Cyclin A2, CDK2
and CDK1 demonstrated diverse amino-acids requirements for
their binding. Crucial Cyclin A2 regions for these interactions
were localized in the N-terminal a-helix, the hydrophobic region
(MRAIL) and the a3 helix of the cyclin box with different
importance for each kinase. First, E180A substitution abolished
Cyclin A2 association with CDK1 while retaining to some extent
its ability to bind to CDK2. However, this association was not
sufficient to induce any kinase activity (Figure 2B). Interestingly,
the corresponding mutation in Xenopus Cyclin A (E176E) abolished
completely its binding to CDKs [18]. An additional difference
with respect to the already published data was observed using
D171A substitution (E167A in Xenopus Cyclin A). This mutation,
proposed to discriminate between CDK1 and CDK2 association
in Xenopus levis cells [18], was not effective in mammalian cells.
Cyclin A2 mutation D171A had no effect in mouse cells, neither
on its association with selected partners nor on its ability to
activate CDKs (Figure 2A).
Furthermore, we investigated the effects of mutations in the
MRAIL motif within the hydrophobic region of the cyclin box.
Previous studies suggested different roles for this motif in Cyclin
A2 functions. While Schulman and co-workers pointed to its
importance in the association with RXL-containing proteins
without affecting binding to CDKs, Jackman and colleagues
suggested that mutations in the MRAIL domain also strongly
affect the association to CDKs [16,17]. To clarify the role of this
domain, we created corresponding mutations in mouse Cyclin A2
in order to address their outcome on its properties. Actually, the
triple substitution M200A, L204A, W207A, completely abolished
any association with all Cyclin A2 partners tested in NIH3T3 cells
and, as a consequence, impaired its kinase activating ability
(Figure 2A). Our results with the Triple mutant are in agreement
with a study performed by Schulman and co-workers with regards
only to Cyclin A2 binding to proteins bearing an RXL motif (p21,
p27 and p107) but not to that of CDK2 [16]. In the latter case, we
confirmed that mutations in MRAIL also strongly affect
associations to CDKs as suggested by Jackman and co-workers.
Furthermore, we extended our analysis by evaluating the role of
each single substitution within the compound mutation. Interest-
ingly any single substitution of these three amino acids did not
recapitulate the behavior of the Triple mutation with respect to
partners binding and CDK-inducing ability (Figure 2 and Table 1).
However, substitution W207A was discriminative for the binding
of Cyclin A2 to CDKs as, under this condition, Cyclin A2 was still
able to bind to CDK1 but not CDK2, and led to histone H1
phosphorylation (Figure 2A).
The most interesting observation obtained by mutagenesis
analysis was the identification of amino acid residues in Cyclin A2
protein contributing to a differential association to CDKs. These
residues were identified in the N-terminal helix (E180A) but also
MRAIL domain (W207A). However, the most striking differences
in discriminating amino acids essential for Cyclin A2 association to
CDK1 and CDK2 were identified after performing mutations in
the regions downstream of the MRAIL motif. The substitutions
tested (Double mutation W207L, E210Q and single mutations
K256A, L282R and E285A) had a moderate effect on Cyclin A2
ability to interact with CDK2. On the other hand, these mutations
strongly affected CDK1 association to Cyclin A2. Thus, we
showed that CDK1 and CDK2 interact differently with specific
Cyclin A2 amino acid residues. Interestingly, even if the Double
(W207L, E210Q) and single K256A mutants were still able to
interact with CDK2 and weakly with CDK1 (K256A), their
kinase-inducing activities were strongly affected (0,51% for the
Double mutant and 2.1% for K256A as referred to 100% for WT
Cyclin A2). All together these observations highlighted the
importance of several domains for promoting kinase activity: N-
terminal a-helix, MRAIL with adjacent domains, and cyclin box
a3 helix.
Other Cyclin A2 partners were tested in this study and
demonstrated diverse binding properties toward the different
Cyclin A2 Mutagenesis Analysis
PLoS ONE | www.plosone.org 2 July 2011 | Volume 6 | Issue 7 | e22879Figure 1. Schematic representation of mouse Cyclin A2 cDNA with the modifications introduced in this study. All constructs were C-
terminally fused to 3 Flag tags.
doi:10.1371/journal.pone.0022879.g001
Figure 2. Analysis of the binding and kinase-activating properties of different Cyclin A2 alleles in NIH3T3 cells. WT, D171A, Triple
(M200A, L204A and W207A), M200A, L204A, W207A (A), and WT, E180A, E210Q, Double (W207L, E210Q), K256A, L282R and E285A Cyclin A2 alleles
(B). Immunoprecipitation using anti-Flag-agarose affinity gel was performed on NIH3T3 cells extracts after transfection of plasmids encoding the
above-mentioned mutants. Immune complexes were either submitted to Western blotting to identify binding partners or analyzed for their histone
H1-kinase activity. Schematic representation of the importance of the different Cyclin A2 domains for partners association and kinase-induced
activity. The bars represent (high-medium-low according to their size) the importance of the indicated region of Cyclin A2 for its association with
partners or kinase inducing activity (C).
doi:10.1371/journal.pone.0022879.g002
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Double and W207A) severely impaired the binding to Cyclin A2
of proteins containing a RXL domain such as p27, p107 and p21.
This is in accordance with previous results published by Schulman
et al. where the corresponding human Cyclin A2 mutant (M210A,
L214A, W217A) was shown to be defective in interacting with the
above-mentioned partners. Surprisingly, mutations located in the
N-terminal a-helix of Cyclin A2 (E180A) also strongly impaired
association of p107 and p21 with Cyclin A2. We also were unable
to detect any p27 association with this mutant under the same
conditions. Finally, the amino acid substitutions located in a3 and
a5 helices (K256A, L282R and E285A) reduced the association of
the tested RXL proteins to Cyclin A2 without abolishing it. All
together these data suggested that each Cyclin A2 partner tested in
this study has particular requirements for its association with this
protein. A schematic representation of the importance of the
different Cyclin A2 domains for partners association and CDK
activation is shown in figure 2C.
In order to study the conservative relevance of these
observations, mouse Cyclin A2 alleles were transfected into
human HEK 293 cells and their association and kinase-activation
ability were assessed. WT, Triple, M200A or D171A alleles
harbored the same properties as in NIH3T3 cells. However,
L204A and W207A alleles showed a different pattern in human
with respect to mouse cells (Figure 3 and Table 2). Whereas the
W207A allele associated with CDK1 but not with CDK2 in
homologous cells, it completely switched its selectivity in human
cells (binding to CDK2 but not CDK1). In addition, L204A allele
demonstrated a reduced affinity to all partners tested in human
cells compared to mouse cells, with a complete loss of affinity to
CDK1.
Requirements for nuclear localization of Cyclin A2
The cellular localization of Cyclin A2 mutants was determined
by immunocytochemical analysis using an antibody against the
Flag-tag as shown in Figure 4. This analysis showed different
localizations for Cyclin A2 alleles. Namely, we were able to detect
them either exclusively in the nucleus or in the cytoplasm, with an
additional classes that exhibited a mixed but predominant nuclear
or cytoplasmic localization. A summary of the sub cellular
localization of all Cyclin A2 mutants is represented in Table 1.
WT and E285A alleles demonstrated a clear exclusive nuclear
localization, whereas L204A, E210Q, K256A and L282R were
predominantly nuclear. On the contrary E180A, W207A, Triple
(M200A, L204A, W207A) and Double (W207L, E210Q) alleles
were located predominantly in the cytoplasm of the cells.
Association to CDK2 has been suggested to be a prerequisite for
nuclear localization of Cyclin A2. However, E180A and Double
(W207L, E210Q) mutant alleles that associate with CDK2 were
found predominantly cytoplasmic. The same was true for CDK1,
since W207A and Double (W207L, E210Q) mutants while still
able to bind this kinase, were predominantly cytoplasmic.
Furthermore, p107 was suggested also to be a potential carrier
of Cyclin A2 to the nucleus. Interestingly, E180A Cyclin A2
mutant, which is still able to bind p107 was found cytoplasmic.
Similarly, p21, another Cyclin A2 partner with an evident NLS,
was also suggested as its nuclear carrier [22]. Surprisingly,
W207A, E180A and Double (W207L, E210Q) mutants, which
are still interacting with p21, harbored a predominant cytoplasmic
localization. Interestingly, only mutant alleles that maintain an
affinity for both p27 and CDK2 (L204A, E210Q, K256A, L282R,
E285A) were found with an exclusive or predominant nuclear
localization.
In order to address the involvement of each Cyclin A2 binding
partners for its nuclear localization, we resorted to the use of p21
2/2,
p27
2/2, p107
2/2, CDK2
2/2 and double p27
2/2, CDK2
2/2
fibroblasts. We observed that cells devoid of p21 and p107 exhibit
a nuclear localization of Cyclin A2 (Figure 5). Surprisingly, neither
the depletion of p27 nor that of CDK2 had any effect on Cyclin A2
nuclear localization, although the latter was suggested as a main
carrier for nuclear import. More surprisingly, depletion of both p27
and CDK2 did not result in a dramatic alteration in Cyclin A2
localization (Figure 5) even though a small proportion of it was
consistently found cytoplasmic (Figure 5). Identical results were
obtained intranfection experiments using Flag tagged WT Cyclin A2
allele followed by immunofluorescence analysis with an anti-Flag
antibody (data not shown).
Interestingly, a deletion analysis failed to unveil any specific
region of Cyclin A2 responsible for its nuclear localization. Both
N- and C-terminal deletion mutants demonstrated both nuclear
Table 1. Summary of binding affinities, kinase activating abilities and cellular localizations of Cyclin A2 alleles in mouse NIH3T3
cells.
CDK 1
(%)
CDK2
(%)
p21
(%)
p27
(%)
p107
(%)
Kinase activity
(%) Cellular localisation
WT 100 100 100 100 100 100 nuclear
D171A 100 100 100 100 100 88,8 NA
M200A 72,8 86,4 100 69,2 79,2 79,6 NA
L204A 57,2 72,4 100 15,2 65,6 71,9 predominant nuclear
W207A 15,3 1,2 79,2 2,3 0 16,7 predominant cytoplasmic
Triple (M200A,L204A, W207A) 0,4 0 0 0 0 0,9 predominant cytoplasmic
E180A 0 17,7 11,7 0 19,6 0 predominant cytoplasmic
E210Q 45,3 99,6 60,2 95,7 70 47,8 predominant nuclear
Double (W207L, E210Q) 9,2 66,4 8,2 0,9 1,8 0,51 predominant cytoplasmic
K256A 3,8 68,2 41,9 19,3 17 2,1 predominant nuclear
L282R 19,8 81,5 65,7 44,5 58,6 18,8 predominant nuclear
E285A 4,7 41,7 78,2 36,7 8,6 3,4 nuclear
Data are represented as percentage relative to WT control taken as 100% upon normalization to Cyclin A2 immunoprecipitation efficiency using densitometric analysis.
doi:10.1371/journal.pone.0022879.t001
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observed. Namely, the N-terminal domain was predominantly
cytoplasmic whereas the C-terminal counterpart was found
predominantly nuclear (Figure 6). These data suggested that
although the C-terminal moiety of the protein was of crucial
importance for its proper nuclear localization, additional domains
in the N-terminal part participated to it.
Discussion
Previous structural studies highlighted the importance of the
hydrophobic region (MRAIL motif) of the first a helix within the
cyclin box for molecular contacts of Cyclin A2 with CDK2
[14,15]. Furthermore, mutagenesis carried out on the human
Cyclin A2 pointed to amino acid residues M210A, L214A,
W217A, as crucial for its association with RXL-containing
partners without affecting its CDK2 kinase-activating ability
[16]. However, subsequent studies identified the MRAIL hydro-
phobic patch of Cyclin A2 as important for its association with
CDKs [17]. We constructed the corresponding mouse Cyclin A2
mutant (M200A, L204A, W207A corresponding to M210A,
L214A, W217A human Cyclin A2) and addressed its association
to some Cyclin A2 partners, its kinase activating properties and
subcellular localization. This allele lost its ability to associate with
any tested Cyclin A2 partner and to induce any kinase activity.
This is in agreement with the studies of Schulman et al. and
Jackman et al. that reported a defective interaction of the
corresponding human Cyclin A2 mutant with RXL containing
proteins (p21, p27 and p107) and CDKs, respectively. In addition,
we confirmed the observation of Jackman and colleagues on the
cytoplasmic localization of this Cyclin A2 mutant. Interestingly,
our analysis demonstrated that the single substitutions (M200A,
L204A or W207A) did not recapitulate the behavior of the Triple
mutation with regards to all properties examined so far. An
identical observation was obtained for the Double W207L, E210Q
substitution. Interestingly, some amino acid residues contributed
differently to the association of Cyclin A2 to CDKs. Thus, the
W207A substitution heavily affected the interaction of Cyclin A2
with CDK2 but in less extent CDK1.
Previous work also stressed the importance of the N-terminal a
helix located upstream of the cyclin box for Cyclin A2 binding
properties in Xenopus levis [18]. We have created the corresponding
mutations (D171A and E180A in mouse by comparison to E167A
and E176A in Xenopus levis). The E167A substitution was described
as discriminative for CDK1 and CDK2 binding in Xenopus.
However, the corresponding D171A mutation, as shown in this
study, had no effect on Cyclin A2 binding to CDK1 or CDK2 in
mammalian cells. On the other hand, we show that the E180A
mutant was deficient in binding CDK1 while still able to associate
to CDK2 even with a reduced efficiency. Although being still able
to bind to CDK2, this allele was not inducing any kinase activity.
Figure 3. Analysis of binding and kinase-activating properties of different Cyclin A2 alleles in HEK 293 cells. WT, Triple (M200A, L204A,
W207A), D171A (A) and M200A, L204A and W207A Cyclin A2 alleles (B). Immunoprecipitation using anti-Flag-agarose affinity gel was performed on
HEK 293 cells extracts after transfection of vectors encoding the above-mentioned mutants. Immune complexes were either submitted to Western
blotting to identify binding partners or analyzed for their histone H1-kinase activity.
doi:10.1371/journal.pone.0022879.g003
Table 2. Summary of binding properties for some Cyclin A2
alleles in human HEK 293 cells.
CDK 1
(%)
CDK2
(%)
p21
(%)
p107
(%)
WT 100 100 100 100
D171A 100 96 94,4 95
M200A 100 100 89,5 57,4
L204A 0 12,6 4,1 5,3
W207A 0 5 0,5 0
Triple (M200A,L204A,
W207A)
00 0 0
Data are represented as percentage relative to WT control taken as 100% upon
normalization to Cyclin A2 immunoprecipitation efficiency using densitometric
analysis.
doi:10.1371/journal.pone.0022879.t002
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PLoS ONE | www.plosone.org 5 July 2011 | Volume 6 | Issue 7 | e22879Figure 4. Immunofluorescence analysis of cellular localization for different Cyclin A2 alleles in NIH3T3 cells. WT, L204A, W207A, Triple
(M200A, L204A, W207A), E180A, E210Q, Double (W207L, E210Q), K256A, L282R and E285A Cyclin A2 alleles. Staining performed using anti-Flag
antibody (green) and Hoechst (blue) in NIH3T3 cells transfected with vectors encoding these Cyclin A2 alleles. Scale bar: 20 mm.
doi:10.1371/journal.pone.0022879.g004
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importance of the N-terminal a helix for Cyclin A2 induced kinase
activity in mammalian cells.
Substitutions in the central and C-terminal parts of the cyclin
box (a helices 3 and 5 respectively) unveiled the importance of
these regions for Cyclin A2 function. Each of these mutations
significantly reduced, but not totally eliminated, the binding of
Cyclin A2 to its partners, resulting in a low kinase-activation
potential. However, cellular localization was not affected.
Moreover, these mutations strongly affected the association to
CDK1, which was not the case for CDK2, suggesting different
requirements for the association with these two kinases.
This study provides evidences that, although sharing some
common features for binding to Cyclin A2, CDK1 and CDK2
have particular requirements for this association. Actually, we
describe a substitution able to discriminate between CDK1 and
CDK2. Namely, the W207A allele binds only to CDK1, whereas
the E180A mutant targets CDK2. This is also confirmed by
substitutions within the a3 and a5 helices from the cyclin box as
discussed above. We also demonstrated that binding to CDKs
does not automatically lead to their activation. Alleles E180A,
Double (W207L, E210Q) and K256A were able to bind to some
extent one or both CDKs without a significant induction in their
kinase activity.
This study sheds a new light on Cyclin A2 cellular localization.
Previous publications suggested a role for CDK2 in this process
although the mechanism remained elusive due to the fact that this
kinase, just like Cyclin A2, has no evident nuclear localization
signal. It was also proposed that Cyclin A2 partners with genuine
NLS signal, such as p107, p130, p21 or members of E2F
transcription factor family could contribute to its import into the
nucleus. Here we demonstrate that binding of Cyclin A2 to p21 or
p107 is not a prerequisite to its nuclear localization. Actually, cells
devoid of these proteins show a clear nuclear localization of Cyclin
A2. However, our experiments couldn’t completely rule out
CDK2 and p27 participation since in their absence some small
amount of Cyclin A2 was detected in the cytoplasm. Furthermore,
we investigated the roles of individual Cyclin A2 domains in its
nuclear localization. Since both N- and C-terminal deletions were
found in the nucleus as well as in the cytoplasm, even though the
C-terminal part appeared to have a predominant role in nuclear
localization, we propose that the whole protein moiety is involved
in its proper subcellular localization.
Materials and Methods
Plasmids and cell lines
Mouse Cyclin A2 cDNA was obtained from NIH3T3 cells by
RT-PCR. Site-directed mutagenesis using QuickChange II
Mutagenesis Kit (Stratagene, Catalog, no. 200523) was performed
after cloning into pBluescriptII(KS) (Stratagene, Catalog,
no. 200455). cDNAs were fused to a 36Flag-tag at their 39 end.
WT and mutated alleles of Cyclin A2 were verified by sequencing.
NIH3T3 (ATCC, No. CRL-1658), HEK 293 (ATCC,
No. CRL-1573), MEFs, p27
2/2 MEFs (kind gift from K.
Nakayama, Nippon Roche Research Center, Kanagawa, Japan),
p107
2/2 MEFs (kind gift from Julien Sage, Stanford University
Medical Center), CDK2
2/2, double CDK2
2/2 p27
2/2 and p21
2/2
3T3 (kind gift from M. Barbacid, CNIO, Madrid, Spain) cells were
maintained in DMEM medium with 10% fetal calf serum (Biowest).
Transfections were performed using Lipofectamine 2000 (Invitro-
gen, Catalog no. 11668-019).
Co-immunoprecipitation and kinase assay
Immunoprecipitations were performed using anti-Flag M2
affinity gel (Sigma, Catalog no. A2220) and precipitates were
either resuspended in Laemmli buffer for western blot analysis or
washed additionally with reaction buffer (20 mM Tris pH 7.5 and
7.5 mM MgCl2) for the kinase assay. Immunoprecipitated
complexes were tested for kinase activity as previously described
[23]. Experiments were repeated 5 and 3 times in NIH3T3 and
HEK 293 cells, respectively. Binding affinities and kinase activity
were quantified using ImageQuantTL software, normalized with
respect to immunoprecipitated Cyclin A2 and represented as
percentage relative to the WT allele taken as 100%.
Antibodies, immunoblotting and immunoflorescence
The following antibodies were used for immunoblotting:
monoclonal anti-Cyclin A2 (clone CY-A1 –Sigma, Catalog
no. C4710), monoclonal anti-Flag antibody (Clone M2, Sigma,
Figure 5. Immunofluorescent analysis of Cyclin A2 localization
in p21
2/2, p107
2/2, p27
2/2, CDK2
2/2 and double p27
2/2CDK2
2/2
genetic backgrounds. Staining was performed using anti-Cyclin A2
antibody (green) for endogenous Cyclin A2. Hoechst (blue) was used for
nuclear staining. Scale bar: 20 mm.
doi:10.1371/journal.pone.0022879.g005
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Catalog no. sc-163), anti-CDK1 (mouse monoclonal, BD Biosci-
ences, Catalog no. C12720-050), anti-p107 (Santa Cruz Biotech-
nology, Catalog no. sc-318.), anti-p21 (Santa Cruz Biotechnology,
Catalog no. sc-397-G), anti-p27 (Santa Cruz Biotechnology,
Catalog no. sc-528-G), Secondary HRP conjugated antibodies
were obtained from Pierce. All immunoblottings were repeated at
least 3 times.
The ant-Flag antibody (Clone M2, Sigma, Catalog no. F9291)
and anti-Cyclin A2 (S. Cruz (H-432) Catalog no. sc-751) with
corresponding AlexaFluor (Invitrogen) secondary antibodies were
used for immunofluorescence staining. Prior to immunofluores-
cence analysis, cells were fixed with 3.2% paraformaldehyde and
permeabilised with 0,2% triton X-100 (anti-Flag) or 220u acetone
(anti-Cyclin A2). After 1 h blocking in 5% BSA cells were incubated
30 min with 1:500 or 1:1000 dilution of primary anti-Flag or anti-
Cyclin A2 antibody respectively. Secondary antibodies were
obtained from Invitrogen-Molecular Probes. Cells were visualized
using Leica DMRA microscope and MetaMorph software. Three
independent immunofluorescence analyses were performed.
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